On the basis of the importance of incretin-based preclinical therapeutics, phase 1/2 clinical studies using GLP1 analogs (liraglutide or semaglutide), GLP-1/GCG receptor dual agonists (cotadutide/MEDI0382), GLP-1/GIP receptor dual agonists (trizepatide/LY3298176 or CT868), and GLP-1/GCG/GIP receptor triple agonists (HM15211) are being conducted in human NASH patients (Table 1). The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.